An Act amending the act of May 13, 2008 (P.L.139, No.14), known as the Cancer Drug Repository Program Act, further providing for title and short title of act, for definitions, for establishment, for restocking and dispensing of cancer drugs, for storage, distribution and fees and for immunity; providing for annual report, for list of approved participating pharmacies and for limitations; further providing for regulations; and imposing duties on the State Board of Pharmacy.
What changed between versions
New definitions were added for 'indigent', 'underinsured', 'uninsured', 'pharmacy benefits manager', 'reverse distributor', and 'third-party logistics provider' to clarify who can participate.
The list of entities allowed to donate drugs was expanded to include reverse distributors, third-party logistics providers, and pharmacy benefits managers.
New requirements mandate compliance with federal and state drug supply chain security laws and electronic system requirements for tracking the chain of custody.
New limitations explicitly prohibit accepting or donating controlled substances and prescription drugs that require manufacturer registration.
The annual report requirement was expanded to include the quantity and estimated value of drugs redistributed under the program.
The deadline for promulgating temporary regulations was changed to December 31, 2027, and the expiration of temporary authority was updated to three years.
The immunity clause was modified to explicitly exclude liability for failure to transfer or communicate expiration date information.
